Hologic (NSDQ:HOLX) won pre-market approval from the FDA for mammography software it says will help reduce patients’ exposure to radiation.

The Bedford, Mass.-based women’s health company said its C-View 2D imaging software is meant to replace conventional 2D exposure, a component of Hologic’s 3D 3D breast tomosynthesis mammography system.

"Large-scale clinical studies have shown that screening with Hologic’s 3D mammography technology allows radiologists to visualize the breast in greater detail than with 2D mammography alone, which results in earlier detection of cancers while at the same time reducing the false positives associated with conventional 2D mammography that cause unnecessary anxiety and cost," Peter Soltani, senior VP of breast health, said in prepared remarks.

Hologic missed its own fiscal Q2 sales forecast and lowered sales and earnings outlooks for the rest of the year. The company also recently announced plans to shutter a plant in Indianapolis that makes breast biopsy products, laying off all 141 workers there.